Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F18%3A00011975" target="_blank" >RIV/00023736:_____/18:00011975 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00103231 RIV/61989592:15110/18:73587842 RIV/65269705:_____/18:00068643 RIV/00179906:_____/18:10386507

Výsledek na webu

<a href="https://doi.org/10.1016/S1470-2045(18)30192-X" target="_blank" >https://doi.org/10.1016/S1470-2045(18)30192-X</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1470-2045(18)30192-X" target="_blank" >10.1016/S1470-2045(18)30192-X</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Popis výsledku v původním jazyce

Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. We aimed to define precise conditions for stopping treatment. This study presents the results of the prespecified interim analysis, which was done after the 6-month molecular relapse-free survival status was known for 200 patients. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries.

Název v anglickém jazyce

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Popis výsledku anglicky

Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. We aimed to define precise conditions for stopping treatment. This study presents the results of the prespecified interim analysis, which was done after the 6-month molecular relapse-free survival status was known for 200 patients. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Lancet oncology

ISSN

1470-2045

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

747-757

Kód UT WoS článku

000434153000041

EID výsledku v databázi Scopus

2-s2.0-85046637421